Advanced Search

Technical Analysis for CARA - Cara Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 12.97 1.17% 0.15
CARA closed up 0.94 percent on Friday, April 3, 2020, on 86 percent of normal volume.
5 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical CARA trend table...
Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 1.17%
Wide Bands Range Expansion 1.17%
20 DMA Support Bullish 2.13%
Wide Bands Range Expansion 2.13%
20 DMA Support Bullish 4.68%
Narrow Range Bar Range Contraction 4.68%
NR7 Range Contraction 4.68%
Stochastic Reached Overbought Strength 4.68%
Wide Bands Range Expansion 4.68%
Overbought Stochastic Strength 4.68%
Older EOD signals for CARA ...
View Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
CARA Chart by TradingView
Basic chart:

Profile

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast

Is CARA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 5 Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
Mar 30 Cannabis Stock Gainers And Losers From March 30, 2020
Mar 25 Covid-19-related activity - healthcare
Mar 25 Cara Therapeutics Reports Clinical Updates
Mar 20 Edited Transcript of CARA earnings conference call or presentation 27-Feb-20 9:30pm GMT
Mar 20 The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Mar 10 3 Beaten-Down Biotech Stocks With Catalysts Just Around the Corner
Mar 4 Cannabis Stock Gainers And Losers From March, 4. 2020
Feb 29 Cara Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
Feb 28 Cara Therapeutics: Scratching At Multiple Indications In 2020
See more CARA news...

Indicators

Indicator Value
52 Week High 27.55
52 Week Low 8.88
Average Volume 493,932
200-Day Moving Average 19.21
50-Day Moving Average 14.69
20-Day Moving Average 12.06
10-Day Moving Average 12.61
Average True Range 1.15
ADX 33.2
+DI 18.81
-DI 25.02
Chandelier Exit (Long, 3 ATRs ) 12.97
Chandelier Exit (Short, 3 ATRs ) 12.32
Upper Bollinger Band 14.74
Lower Bollinger Band 9.38
Percent B (%b) 0.64
BandWidth 44.45
MACD Line -0.51
MACD Signal Line -0.82
MACD Histogram 0.3059
Fundamentals Value
Market Cap 417.68 Million
Num Shares 32.6 Million
EPS -2.28
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Sales 424.16
Price-to-Book 3.54
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.92
Resistance 3 (R3) 13.88 13.47 13.73
Resistance 2 (R2) 13.47 13.19 13.49 13.67
Resistance 1 (R1) 13.15 13.02 13.31 13.19 13.61
Pivot Point 12.74 12.74 12.83 12.76 12.74
Support 1 (S1) 12.42 12.46 12.58 12.46 12.03
Support 2 (S2) 12.01 12.29 12.03 11.97
Support 3 (S3) 11.69 12.01 11.91
Support 4 (S4) 11.73